FT-001 is under clinical development by Frontera Therapeutics and currently in Phase II for Leber Congenital Amaurosis (LCA). According to GlobalData, Phase II drugs for Leber Congenital Amaurosis (LCA) have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FT-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FT-001 is under development for the treatment of leber congenital amaurosis-2 (LCA) and rare ophthalmological disorder RPE65 biallelic variant-associated retinal degeneration. It is an adeno-associated virus (AVV) vector mediated gene therapy. It is administered through intraocular route. It is being developed based on APEX technology and manufacturing platform.
It was also under development for the treatment of liver diseases.
Frontera Therapeutics overview
Frontera Therapeutics Co., Ltd (Frontera Therapeutics) is a company that develop cost-effective recombinant adeno-associated virus (rAAV) based gene therapies. The company is Headquartered in United States.
For a complete picture of FT-001’s drug-specific PTSR and LoA scores, buy the report here.